Transcriptional profile of primary astrocytes expressing ALS-linked mutant SOD1

✍ Scribed by Marcelo R. Vargas; Mariana Pehar; Pablo J. Díaz-Amarilla; Joseph S. Beckman; Luis Barbeito

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 247 KB
• Volume: 86
• Category: Article
• ISSN: 0360-4012
• DOI: 10.1002/jnr.21797

✦ Synopsis

Abstract

Amyotrophic lateral sclerosis (ALS) is caused by the progressive degeneration of motor neurons. Mutations in the Cu/Zn superoxide dismutase (SOD1) are found in approximately 20% of patients with familial ALS. Mutant SOD1 causes motor neuron death through an acquired toxic property. Although the molecular mechanism underlying this toxic gain‐of‐function remains unknown, evidence support the role of mutant SOD1 expression in nonneuronal cells in shaping motor neuron degeneration. We have previously found that in contrast to nontransgenic cells, SOD1^G93A^‐expressing astrocytes induced apoptosis of cocultured motor neurons. This prompted us to investigate whether the effect on motor neuron survival was related to a change in the gene expression profile. Through high‐density oligonucleotide microarrays, we found changes in the expression of genes involved in transcription, signaling, cell proliferation, extracellular matrix synthesis, response to stress, and steroid and lipid metabolism. The most up‐regulated gene was decorin (Dcn), a small multifunctional extracellular proteoglycan. Down‐regulated genes included the insulin‐like growth factor‐1 receptor (Igf‐1r) and the RNA binding protein ROD1. Rod1 was also found down‐regulated in purified motor neurons expressing SOD1^G93A^. Changes in the expression of Dcn, Igf‐1r, and Rod1 were found in the spinal cord of asymptomatic animals, suggesting these changes occur before overt neuronal degeneration and potentially influence astrocyte–motor neuron interaction in the course of the disease. The astrocyte‐specific gene expression profile might contribute to the identification of possible candidates for cell type‐specific therapies in ALS. © 2008 Wiley‐Liss, Inc.